Get Funding for Cancer Biomarker Research!
Summary
This grant offers cooperative funding for labs developing and refining biomarkers for early cancer detection, risk assessment, and diagnosis. Eligible entities can receive significant support to advance critical research in cancer diagnostics.
Eligibility
Full Description
Purpose. This funding opportunity announcement (FOA) solicits cooperative agreement applications for Biomarker Developmental Laboratories (BDLs), one of the four components of the Early Detection Research Network (EDRN). EDRN is a national consortium funded to discover, develop, and validate biomarkers for early cancer detection, risk assessment, and the molecular diagnosis and prognosis of early cancer.. The BDLs have responsibility for the development and characterization of new, or the refinement of existing, biomarkers and biomarker assays.
The other three main components of the EDRN are: the Biomarker Reference Laboratories (BRLs), which serve as Network resources for clinical and laboratory validation of biomarkers; the Clinical Validation Centers (CVCs), which conduct clinical research on the validation of biomarkers in early cancer detection and risk assessment and serve as resource centers for the EDRN by participating in collaborative biomarker validation studies and collaborating with EDRN BDLs and BRLs; and the Data Management and Coordinating Center (DMCC), which supports statistical and computational analyses, informatics infrastructure, and the coordination of network-wide meetings and conferences. Mechanism of Support. This FOA utilizes the NIH Cooperative Agreement (U01) award mechanism. Parallel FOAs for other EDRN components include RFA-CA-09-018 (U01) for CVCs, RFA-CA-09-019 (U24) for BRLs, and RFA-CA-09-020 (U24) for DMCC.
Funds Available and Anticipated Number of Awards. The NCI expects to commit $10-11 million per year to fund 20 - 25 BDLs.